Q1 Earnings Forecast for SXTP Issued By HC Wainwright

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of 60 Degrees Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 25th. HC Wainwright analyst E. White anticipates that the company will earn ($2.81) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.53) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Wednesday, February 19th.

60 Degrees Pharmaceuticals Trading Down 9.4 %

Shares of SXTP stock opened at $1.92 on Wednesday. 60 Degrees Pharmaceuticals has a 12-month low of $1.78 and a 12-month high of $35.99. The business’s 50 day moving average is $0.97 and its two-hundred day moving average is $1.13. The company has a market capitalization of $14.14 million, a P/E ratio of -0.19 and a beta of 4.22.

Insider Activity

In related news, CEO Geoffrey S. Dow purchased 7,164 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average cost of $6.35 per share, with a total value of $45,491.40. Following the purchase, the chief executive officer now owns 18,916 shares of the company’s stock, valued at $120,116.60. This represents a 60.96 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased a total of 12,073 shares of company stock worth $76,966 over the last 90 days. 10.27% of the stock is currently owned by company insiders.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.